Perttu Koskenvesa

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients.

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients.

Journal: HemaSphere

Published: October 23, 2025

Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.

Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.

Journal: Leukemia

Published: May 21, 2025

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.

Journal: Leukemia

Published: April 23, 2024

Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.

Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.

Journal: Leukemia

Published: February 28, 2024

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.

Journal: Leukemia

Published: November 01, 2023

Real-world experience of novel multiple myeloma treatments in a large, single-center cohort in Finland.

Real-world experience of novel multiple myeloma treatments in a large, single-center cohort in Finland.

Journal: EJHaem

Published: July 03, 2023

Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Journal: Haematologica

Published: December 23, 2021

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.

Journal: Blood cancer journal

Published: December 21, 2021

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.

Journal: The Journal of clinical investigation

Published: July 06, 2021

Ponatinib-induced ichthyosiform eruption.

Ponatinib-induced ichthyosiform eruption.

Journal: EJHaem

Published: May 05, 2021

Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.

Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.

Journal: European journal of haematology

Published: April 05, 2021

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.

Journal: Leukemia

Published: November 09, 2020

Showing 1-12 of 34

Last Updated: 09/26/2026